Panelists discuss how communication between clinicians, patients, and payers could improve equitable access to spinal ...

Panelists discuss how spinal muscular atrophy (SMA) treatment will evolve over the next 5 years, likely incorporating ...

Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients ...

John Mascarenhas, MD, discusses phase 1 data showing that INCA33989 is a well-tolerated therapy for calreticulin–mutant essential thrombocythemia, with early signs of efficacy and potential disease ...

South Carolina had previously barred abortion clinics, including Planned Parenthood, from participating in Medicaid, leaving many patients vulnerable to uncovered treatment.

Iptacopan targets one of the major proteins involved in the enzymes of the alternative pathway of complement, explains Carla ...

New data show sharp growth in pharmacists’ clinical roles, from the intensive care unit to outpatient chronic disease ...

The hazard of the progression of intermediate age-related macular degeneration (iAMD) was higher in those whose complement ...

Patients with early-stage melanoma who experience relapse following wide local excision face worse survival outcomes.

John Mascarenhas, MD, discusses the rationale, mechanism, and design of the phase 1 INCA33989-101 and -102 trials investigating a CAL-R–targeted antibody for patients with essential thrombocythemia.

On-body delivery systems for subcutaneous isatuximab could enable patient self-administration, according to Xavier Leleu, MD, PhD, improving convenience and transforming treatment for ...

Compared with tezepelumab, solrikitug demonstrated unique epitope binding and superior potency across several assays.